PriceTargets.com logo

Humacyte - HUMA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $13.00
  • Forecasted Upside: 242.56%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 1 Strong Buy Ratings
$3.80 As of 12/17/2024 01:00 AM ET
▼ -0.54 (-12.46%)

This chart shows the closing price for HUMA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Humacyte Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HUMA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HUMA

Analyst Price Target is $13.00
▲ +242.56% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Humacyte in the last 3 months. The average price target is $13.00, with a high forecast of $25.00 and a low forecast of $6.00. The average price target represents a 242.56% upside from the last price of $3.80.

This chart shows the closing price for HUMA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 8 contributing investment analysts is to buy stock in Humacyte. This rating has held steady since August 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/22/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/20/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/18/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/17/2024

Latest Recommendations

  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/21/2024D. Boral CapitalReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
11/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
11/5/2024HC WainwrightBoost TargetBuy ➝ Buy$6.00 ➝ $12.00
10/18/2024Piper SandlerSet TargetNeutral ➝ Neutral$6.00
10/18/2024TD CowenReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
10/18/2024BTIG ResearchReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
10/10/2024BenchmarkReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
9/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$13.00 ➝ $13.00
9/9/2024EF Hutton Acquisition Co. IUpgradeStrong-Buy
9/5/2024BenchmarkReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
8/12/2024BenchmarkReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
7/15/2024BTIG ResearchBoost TargetBuy ➝ Buy$8.00 ➝ $11.00
7/2/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$7.00 ➝ $7.00
7/2/2024BenchmarkReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
5/24/2024BenchmarkReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
5/13/2024BenchmarkReiterated RatingBuy ➝ Buy$15.00
4/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$7.00
3/26/2024Piper SandlerReiterated RatingNeutral ➝ Neutral$4.00
3/25/2024BenchmarkReiterated RatingBuy ➝ Buy$15.00
12/27/2023BenchmarkLower TargetBuy ➝ Buy$16.00 ➝ $15.00
12/11/2023HC WainwrightInitiated CoverageBuy$6.00
11/10/2023Piper SandlerLower TargetNeutral ➝ Neutral$3.50 ➝ $3.00
9/21/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$7.00
8/31/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$6.00
8/24/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$6.00
8/15/2023BenchmarkReiterated RatingBuy ➝ Buy$16.00
8/14/2023Piper SandlerUpgradeUnderweight ➝ Neutral$2.75 ➝ $3.50
6/22/2023Cantor FitzgeraldInitiated CoverageOverweight$6.00
3/27/2023BenchmarkReiterated RatingBuy$16.00
12/19/2022CowenLower Target$8.00 ➝ $5.00
11/16/2022Piper SandlerLower Target$2.75
11/10/2022Piper SandlerLower Target$3.50 ➝ $2.75
10/20/2022BTIG ResearchLower Target$9.00
8/12/2022Piper SandlerLower Target$4.00 ➝ $3.50
7/18/2022BTIG ResearchLower TargetBuy$12.00 ➝ $10.00
5/15/2022Piper SandlerDowngradeOverweight ➝ Underweight$10.00 ➝ $4.00
3/29/2022Piper SandlerLower Target$17.00 ➝ $10.00
10/29/2021CowenInitiated CoverageOutperform$17.00
9/23/2021OppenheimerInitiated CoverageOutperform$16.00
9/22/2021BTIG ResearchInitiated CoverageBuy$19.00
9/16/2021Piper SandlerInitiated CoverageOverweight$17.00
(Data available from 12/18/2019 forward)

News Sentiment Rating

0.20 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 19 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2024
  • 11 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 11 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2024
  • 6 very positive mentions
  • 21 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
Mentions as of
8/20/2024
  • 7 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2024
  • 12 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2024
  • 7 very positive mentions
  • 42 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2024
  • 16 very positive mentions
  • 117 positive mentions
  • 6 negative mentions
  • 3 very negative mentions
Mentions as of
12/18/2024

Current Sentiment

  • 16 very positive mentions
  • 117 positive mentions
  • 6 negative mentions
  • 3 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Humacyte logo
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $3.80
Low: $3.56
High: $4.42

50 Day Range

MA: $4.93
Low: $3.80
High: $5.82

52 Week Range

Now: $3.80
Low: $2.48
High: $9.97

Volume

5,753,557 shs

Average Volume

2,429,610 shs

Market Capitalization

$477.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.38

Frequently Asked Questions

What sell-side analysts currently cover shares of Humacyte?

The following sell-side analysts have issued stock ratings on Humacyte in the last year: Benchmark Co., BTIG Research, Cantor Fitzgerald, D. Boral Capital, EF Hutton Acquisition Co. I, HC Wainwright, Piper Sandler, and TD Cowen.
View the latest analyst ratings for HUMA.

What is the current price target for Humacyte?

0 Wall Street analysts have set twelve-month price targets for Humacyte in the last year. Their average twelve-month price target is $13.00, suggesting a possible upside of 242.6%. D. Boral Capital has the highest price target set, predicting HUMA will reach $25.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $6.00 for Humacyte in the next year.
View the latest price targets for HUMA.

What is the current consensus analyst rating for Humacyte?

Humacyte currently has 1 hold rating, 6 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HUMA will outperform the market and that investors should add to their positions of Humacyte.
View the latest ratings for HUMA.

What other companies compete with Humacyte?

Other companies that are similar to Humacyte include Apogee Therapeutics, ImmunityBio, Wave Life Sciences, Mirum Pharmaceuticals and Akero Therapeutics. Learn More about companies similar to Humacyte.

How do I contact Humacyte's investor relations team?

Humacyte's physical mailing address is 1177 AVENUE OF THE AMERICAS 5TH FLOOR, NEW YORK NY, 10036. The company's listed phone number is 919-313-9633 and its investor relations email address is [email protected]. The official website for Humacyte is www.constellationalpha.com. Learn More about contacing Humacyte investor relations.